Graft-versus-host disease: Part II. Management of cutaneous graft-versus-host disease

Journal of the American Academy of Dermatology

Volumn 66, Issue 4, 2012, Pages 535.e1-535.e16

  Hymes, Sharon R ^a   Alousi, Amin M ^b   Cowen, Edward W ^c  

^a University of Texas Health Science Center at Houston   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cyclosporine; extracorporeal photopheresis; graft versus host disease; hematopoietic cell transplantation; imatinib mesylate; mycophenolate mofetil; phototherapy; rituximab; tacrolimus

Indexed keywords

ALEFACEPT; CLOBETASOL; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; EVEROLIMUS; FLUOCINONIDE; IMATINIB; INFLIXIMAB; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PSORALEN; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ANOREXIA; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; GENITAL SYSTEM DISEASE; GINGIVA HYPERPLASIA; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; MESENCHYMAL STEM CELL; MOUTH DISEASE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PUVA; SEIZURE; SKIN MANIFESTATION; SKIN TUMOR; SYSTEMIC THERAPY; TREMOR; ULTRAVIOLET RADIATION; WOUND CARE;

EID: 84858302314     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.11.961     Document Type: Review

References (133)

1. D. Couriel, P.A. Carpenter, C. Cutler, J. Bolaños-Meade, N.S. Treister, and J. Gea-Banacloche Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-host Disease: V. Ancillary Therapy and Supportive Care Working Group Report Biol Blood Marrow Transplant 12 2006 375 396
2. S. Elad, R. Or, I. Resnick, and M.Y. Shapira Topical tacrolimus - a novel treatment alternative for cutaneous chronic graft-versus-host disease Transpl Int 16 2003 665 670
3. C.J. Choi, and P. Nghiem Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients Arch Dermatol 137 2001 1202 1206
4. T. Schmook, J. Kraft, B. Benninghoff, I. Nindl, J. Roewert, and C. Ulrich Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus Bone Marrow Transplant 36 2005 87 88
5. D.L. Neuman, J.E. Farrar, J.M. Moresi, G.B. Vogelsang, and M.A. Higman Toxic absorption of tacrolimus [corrected] in a patient with severe acute graft-versus-host disease Bone Marrow Transplant 36 2005 919 920
6. I.S. Choi, I.S. Jang, J.Y. Han, J.H. Kim, and S.G. Lee Therapeutic experience on multiple contractures in sclerodermoid chronic graft versus host disease Support Care Cancer 17 2009 851 855
7. M. Tomblyn, T. Chiller, H. Einsele, R. Gress, K. Sepkowitz, and J. Storek Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Biol Blood Marrow Transplant 15 2009 1143 1238
8. Y.M. Markus, M.J. Bell, and A.W. Evans Ischemic scleroderma wounds successfully treated with hyperbaric oxygen therapy J Rheumatol 33 2006 1694 1696
9. J.O. Berg, L. Vindelov, G. Schmidt, and K.T. Drzewiecki Allogeneic split-skin grafting in stem cell transplanted patients J Plast Reconstr Aesthet Surg 61 2008 1512 1515
10. A. Eckardt, O. Starke, M. Stadler, C. Reuter, and B. Hertenstein Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus Oral Oncol 40 2004 811 814
11. D. Conrotto, M. Carrozzo, A.V. Ubertalli, S. Gandolfo, L. Giaccone, and M. Boccadoro Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease Transplantation 82 2006 1113 1115
12. J.B. Epstein, S. Nantel, and S.M. Sheoltch Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease Bone Marrow Transplant 25 2000 683 687
13. L.B. Spiryda, M.R. Laufer, R.J. Soiffer, and J.A. Antin Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment Biol Blood Marrow Transplant 9 2003 760 765
14. M.L. Turner, and P. Stratton Gynecological manifestations of chronic graft versus host disease G. Vogelsang, S. Pavletic, Chronic graft versus host disease: interdisciplinary management 2009 Cambridge University Press Cambridge (UK) 207 215
15. Yared J, Gojo I, Akpek G. Glans penis involvement: an under-recognized manifestation of chronic GVHD. Bone Marrow Transplant doi: 10.1038/bmt.2011.209. Published online November 7, 2011.
16. T. Kitajima, and S. Imamura Graft-versus-host reaction enhanced by ultraviolet radiation Arch Dermatol Res 285 1993 499 501
17. G.M. Murphy Ultraviolet radiation and immunosuppression Br J Dermatol 161 suppl 3 2009 90 95
18. M. Ozawa, K. Ferenczi, T. Kikuchi, I. Cardinale, L.M. Austin, and T.R. Coven 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions J Exp Med 189 1999 711 718
19. M.L. Kripke, W.L. Morison, and J.A. Parrish Systemic suppression of contact hypersensitivity in mice by psoralen plus UVA radiation (PUVA) J Invest Dermatol 81 1983 87 92
20. S.R. Hymes, W.L. Morison, E.R. Farmer, L.L. Walters, P.J. Tutschka, and G.W. Santos Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction J Am Acad Dermatol 12 1985 30 37
21. J. Ashworth, M.C. Kahan, and S.M. Breathnach PUVA therapy decreases HLA-DR+ CDIa+ Langerhans cells and epidermal cell antigen-presenting capacity in human skin, but flow cytometrically-sorted residual HLA-DR+ CDIa+ Langerhans cells exhibit normal alloantigen-presenting function Br J Dermatol 120 1989 329 339
22. T.Y. Kim, M.L. Kripke, and S.E. Ullrich Immunosuppression by factors released from UV-irradiated epidermal cells: selective effects on the generation of contact and delayed hypersensitivity after exposure to UVA or UVB radiation J Invest Dermatol 94 1990 26 32
23. K. Kang, C. Hammerberg, L. Meunier, and K.D. Cooper CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein J Immunol 153 1994 5256 5264
24. M. Grundmann-Kollmann, H. Martin, R. Ludwig, S. Klein, W.H. Boehncke, and D. Hoelzer Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease Transplantation 74 2002 1631 1634
25. G.B. Vogelsang, D. Wolff, V. Altomonte, E. Farmer, W.L. Morison, and R. Corio Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA) Bone Marrow Transplant 17 1996 1061 1067
26. U. Leiter, P. Kaskel, G. Krahn, P. Gottlober, D. Bunjes, and R.U. Peter Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease Photodermatol Photoimmunol Photomed 18 2002 183 190
27. C.D. Enk, S. Elad, A. Vexler, J. Kapelushnik, R. Gorodetsky, and M. Kirschbaum Chronic graft-versus-host disease treated with UVB phototherapy Bone Marrow Transplant 22 1998 1179 1183
28. V. Brazzelli, V. Grasso, F. Muzio, E. Moggio, M. Zecca, and F. Locatelli Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients Br J Dermatol 162 2010 404 409
29. M. Grundmann-Kollmann, S. Behrens, C. Gruss, P. Gottlober, R.U. Peter, and M. Kerscher Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy J Am Acad Dermatol 42 2000 134 136
30. M. Ziemer, J.J. Thiele, B. Gruhn, and P. Elsner Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy: improvement of skin lesions, joint mobility, and quality of life J Am Acad Dermatol 51 2004 318 319
31. T. Wetzig, M. Sticherling, J.C. Simon, U. Hegenbart, D. Niederwieser, and H.K. Al-Ali Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin Bone Marrow Transplant 35 2005 515 519
32. E.W. Cowen, J.C. Nguyen, D.D. Miller, D. McShane, S.T. Arron, and N.S. Prose Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole J Am Acad Dermatol 62 2010 31 37
33. A. Vadnerkar, M.H. Nguyen, D. Mitsani, M. Crespo, J. Pilewski, and Y. Toyoda Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients J Heart Lung Transplant 29 2010 1240 1244
34. D.D. Miller, E.W. Cowen, J.C. Nguyen, T.H. McCalmont, and L.P. Fox Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity Arch Dermatol 146 2010 300 304
35. H.J. Kolb, G. Socie, T. Duell, M.T. Van Lint, A. Tichelli, and J.F. Apperley Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group Ann Intern Med 131 1999 738 744
36. V. Andreani, M.A. Richard, D. Blaise, J. Gouvernet, and J.J. Grob Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi Br J Dermatol 147 2002 433 441
37. R.E. Curtis, P.A. Rowlings, H.J. Deeg, D.A. Shriner, G. Socie, and L.B. Travis Solid cancers after bone marrow transplantation N Engl J Med 336 1997 897 904
38. E.M. Sloand, L. Pfannes, C. Ling, X. Feng, M. Jasek, and R. Calado Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes Biol Blood Marrow Transplant 16 2010 1665 1673
39. W. Leisenring, D.L. Friedman, M.E. Flowers, J.L. Schwartz, and H.J. Deeg Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation J Clin Oncol 24 2006 1119 1126
40. C.H. Szeto, T.W. Shek, A.K. Lie, W.Y. Au, A.P. Yuen, and Y.L. Kwong Squamous cell carcinoma of the tongue complicating chronic oral mucosal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Am J Hematol 77 2004 200 202
41. S. Garnis, R.C. Billick, and H. Srolovitz Eruptive vascular tumors associated with chronic graft-versus-host disease J Am Acad Dermatol 10 1984 918 921
42. J.K. Soo, and P.S. Mortimer Eruptive angiomas associated with graft-versus-host disease Br J Dermatol 154 2006 376 378
43. H. Adamski, F. Le Gall, L. Cartron, C. Dauriac, G. Lancien, and J. Wechsler Eruptive angiomatous lesions associated with graft-versus-host disease Br J Dermatol 149 2003 667 668
44. J.H. Kunishige, S.R. Hymes, V. Madkan, A.J. Wyatt, D. Uptmore, and A.J. Lazar Epidermodysplasia verruciformis in the setting of graft-versus-host disease J Am Acad Dermatol 57 5 suppl 2007 S78 S80
45. M.L. Diamantis, H.M. Richmond, P.L. Rady, S.K. Tyring, J.E. Cutlan, and C. Torres-Cabala Detection of human papillomavirus in multiple eccrine poromas in a patient with chronic graft-vs-host disease and immunosuppression Arch Dermatol 147 2011 120 122
46. J.R. Wingard, S. Piantadosi, G.B. Vogelsang, E.R. Farmer, D.A. Jabs, and L.S. Levin Predictors of death from chronic graft-versus-host disease after bone marrow transplantation Blood 74 1989 1428 1435
47. G. Akpek, M.L. Zahurak, S. Piantadosi, J. Margolis, J. Doherty, and R. Davidson Development of a prognostic model for grading chronic graft-versus-host disease Blood 97 2001 1219 1226
48. K.M. Sullivan, R.P. Witherspoon, R. Storb, P. Weiden, N. Flournoy, and S. Dahlberg Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation Blood 72 1988 546 554
49. A.Z. Dudek, H. Mahaseth, T.E. DeFor, and D.J. Weisdorf Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes Biol Blood Marrow Transplant 9 2003 657 666
50. M. Arora, J.P. Klein, D.J. Weisdorf, A. Hassebroek, M.E. Flowers, and C.S. Cutler Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis Blood 117 2011 6714 6720
51. J.A. Pérez-Simón, C. Encinas, F. Silva, M.J. Arcos, M. Díez-Campelo, and F.M. Sánchez-Guijo Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the National Institutes Health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy Biol Blood Marrow Transplant 14 2008 1163 1171
52. B.L. Stewart, B. Storer, J. Storek, H.J. Deeg, R. Storb, and J.A. Hansen Duration of immunosuppressive treatment for chronic graft-versus-host disease Blood 104 2004 3501 3506
53. P.J. Martin, G. Schoch, L. Fisher, V. Byers, F.R. Appelbaum, and G.B. McDonald A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment Blood 77 1991 1821 1828
54. M.T. Van Lint, C. Uderzo, A. Locasciulli, I. Majolino, R. Scime, and F. Locatelli Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation Blood 92 1998 2288 2293
55. A.M. Alousi, D.J. Weisdorf, B.R. Logan, J. Bolanos-Meade, S. Carter, and N. Difronzo Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network Blood 114 2009 511 517
56. L. Cragg, B.R. Blazar, T. Defor, N. Kolatker, W. Miller, and J. Kersey A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease Biol Blood Marrow Transplant 6 2000 441 447
57. D.R. Couriel, R. Saliba, M. de Lima, S. Giralt, B. Andersson, and I. Khouri A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease Biol Blood Marrow Transplant 15 2009 1555 1562
58. D. Weisdorf, R. Haake, B. Blazar, W. Miller, P. McGlave, and N. Ramsay Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome Blood 75 1990 1024 1030
59. R. Storb, H.J. Deeg, J. Whitehead, F. Appelbaum, P. Beatty, and W. Bensinger Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia N Engl J Med 314 1986 729 735
60. S.J. Rossi, T.J. Schroeder, S. Hariharan, and M.R. First Prevention and management of the adverse effects associated with immunosuppressive therapy Drug Saf 9 1993 104 131
61. V. Ratanatharathorn, R.A. Nash, D. Przepiorka, S.M. Devine, J.L. Klein, and D. Weisdorf Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 92 1998 2303 2314
62. V. Bhushan, and R.H. Collins Jr. Chronic graft-vs-host disease JAMA 290 2003 2599 2603
63. S. Koc, W. Leisenring, M.E. Flowers, C. Anasetti, H.J. Deeg, and R.A. Nash Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone Blood 100 2002 48 51
64. P.J. Martin, B.E. Storer, S.D. Rowley, M.E. Flowers, S.J. Lee, and P.A. Carpenter Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease Blood 113 2009 5074 5082
65. R. Zeiser, V.H. Nguyen, A. Beilhack, M. Buess, S. Schulz, and J. Baker Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production Blood 108 2006 390 399
66. D. Wolff, A. Gerbitz, F. Ayuk, A. Kiani, G.C. Hildebrandt, and G.B. Vogelsang Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD Biol Blood Marrow Transplant 16 2010 1611 1628
67. D. Wolff, M. Schleuning, S. von Harsdorf, U. Bacher, A. Gerbitz, and M. Stadler Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease Biol Blood Marrow Transplant 17 2011 1 17
68. D. Peritt Potential mechanisms of photopheresis in hematopoietic stem cell transplantation Biol Blood Marrow Transplant 12 2006 7 12
69. E. Gatza, C.E. Rogers, S.G. Clouthier, K.P. Lowler, I. Tawara, and C. Liu Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells Blood 112 2008 1515 1521
70. E.D. Seaton, R.M. Szydlo, E. Kanfer, J.F. Apperley, and R. Russell-Jones Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response Blood 102 2003 1217 1223
71. D.R. Couriel, C. Hosing, R. Saliba, E.J. Shpall, P. Anderlini, and B. Rhodes Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD Blood 107 2006 3074 3080
72. M.E. Flowers, J.F. Apperley, K. van Besien, A. Elmaagacli, A. Grigg, and V. Reddy A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease Blood 112 2008 2667 2674
73. C. Romano, P. Rubegni, G. De Aloe, E. Stanghellini, G. D'Ascenzo, and L. Andreassi Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis J Eur Acad Dermatol Venereol 17 2003 10 13
74. A.R. Patel, D. Avila, H.L. Malech, S.Z. Pavletic, L. Yao, and E.W. Cowen Rippled skin, fasciitis, and joint contractures J Am Acad Dermatol 59 2008 1070 1074
75. P. Sbano, P. Rubegni, G.B. De Aloe, S. Guidi, and M. Fimiani Extracorporeal photochemotherapy for treatment of fasciitis in chronic graft-versus-host disease Bone Marrow Transplant 33 2004 869 870
76. S.R. Marshall Technology insight: ECP for the treatment of GvHD - can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 3 2006 302 314
77. S.Z. Pavletic, P. Martin, S.J. Lee, S. Mitchell, D. Jacobsohn, and E.W. Cowen Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report Biol Blood Marrow Transplant 12 2006 252 266
78. J. Park, H. Ha, H.J. Ahn, S.W. Kang, Y.S. Kim, and J.Y. Seo Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis in rat vascular smooth muscle cells Transplant Proc 37 2005 3459 3462
79. Z. Jedlickova, I. Burlakova, G. Bug, H. Baurmann, R. Schwerdtfeger, and M. Schleuning Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors Biol Blood Marrow Transplant 17 2011 657 663
80. D.R. Couriel, R. Saliba, M.P. Escalon, Y. Hsu, S. Ghosh, and C. Ippoliti Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease Br J Haematol 130 2005 409 417
81. M. Jurado, C. Vallejo, J.A. Perez-Simon, S. Brunet, C. Ferra, and P. Balsalobre Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease Biol Blood Marrow Transplant 13 2007 701 706
82. K. Schultz Pathophysiology of chronic graft-versus-host disease G. Vogelsang, S. Pavletic, Chronic graft versus host disease: interdisciplinary management 2009 Cambridge University Press Cambridge (UK) 17 30
83. J. Rosenbloom, S.V. Castro, and S.A. Jimenez Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies Ann Intern Med 152 2010 159 166
84. S.S. Baroni, M. Santillo, F. Bevilacqua, M. Luchetti, T. Spadoni, and M. Mancini Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis N Engl J Med 354 2006 2667 2676
85. S. Svegliati, A. Olivieri, N. Campelli, M. Luchetti, A. Poloni, and S. Trappolini Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease Blood 110 2007 237 241
86. L. Magro, M. Mohty, B. Catteau, V. Coiteux, P. Chevallier, and L. Terriou Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease Blood 114 2009 719 722
87. A. Olivieri, F. Locatelli, M. Zecca, A. Sanna, M. Cimminiello, and R. Raimondi Imatinib for refractory chronic graft-versus-host disease with fibrotic features Blood 114 2009 709 718
88. D. Dragun, J.H. Distler, G. Riemekasten, and O. Distler Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology Arthritis Rheum 60 2009 907 911
89. H. Nakasone, Y. Kanda, H. Takasaki, C. Nakaseko, T. Sakura, and S. Fujisawa Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia Leukemia 24 2010 1236 1239
90. R. Seggewiss, K. Lore, E. Greiner, M.K. Magnusson, D.A. Price, and D.C. Douek Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner Blood 105 2005 2473 2479
91. M. Breccia, L. Cannella, C. Stefanizzi, A. Carotti, M. Santopietro, and G. Alimena Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Bone Marrow Transplant 44 2009 331 332
92. D. Pulanic, E.W. Cowen, K. Baird, M.R. Bishop, and S.Z. Pavletic Development of severe sclerotic chronic GVHD during treatment with dasatinib Bone Marrow Transplant 45 2010 1469 1470
93. J.P. Uberti, L. Ayash, V. Ratanatharathorn, S. Silver, C. Reynolds, and M. Becker Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease Biol Blood Marrow Transplant 11 2005 680 687
94. A. Busca, F. Locatelli, F. Marmont, C. Ceretto, and M. Falda Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation Am J Hematol 82 2007 45 52
95. J.E. Levine, S. Paczesny, S. Mineishi, T. Braun, S.W. Choi, and R.J. Hutchinson Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease Blood 111 2008 2470 2475
96. J. Pidala, J. Kim, T. Field, A. McBride, M. Kharfan-Dabaja, and J. Perkins Infliximab for managing steroid-refractory acute graft-versus-host disease Biol Blood Marrow Transplant 15 2009 1116 1121
97. D. Couriel, R. Saliba, K. Hicks, C. Ippoliti, M. de Lima, and C. Hosing Tumor necrosis factor-alpha blockade for the treatment of acute GVHD Blood 104 2004 649 654
98. K.Y. Chiang, S. Abhyankar, K. Bridges, K. Godder, and J.P. Henslee-Downey Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease Transplantation 73 2002 665 667
99. F.M. Marty, S.J. Lee, M.M. Fahey, E.P. Alyea, R.J. Soiffer, and J.H. Antin Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study Blood 102 2003 2768 2776
100. J.A. Keifer, D.C. Guttridge, B.P. Ashburner, and A.S. Baldwin Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity J Biol Chem 276 2001 22382 22387
101. E.R. Lepper, N.F. Smith, M.C. Cox, C.D. Scripture, and W.D. Figg Thalidomide metabolism and hydrolysis: mechanisms and implications Curr Drug Metab 7 2006 677 685
102. M.Y. Shapira, A. Abdul-Hai, I.B. Resnick, M. Bitan, P. Tsirigotis, and M. Aker Alefacept treatment for refractory chronic extensive GVHD Bone Marrow Transplant 43 2009 339 343
103. V. Ratanatharathorn, L. Ayash, C. Reynolds, S. Silver, P. Reddy, and M. Becker Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody Biol Blood Marrow Transplant 9 2003 505 511
104. M.R. Canninga-van Dijk, H.M. van der Straaten, R. Fijnheer, C.J. Sanders, J.G. van den Tweel, and L.F. Verdonck Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease Blood 104 2004 2603 2606
105. C. Cutler, D. Miklos, H.T. Kim, N. Treister, S.B. Woo, and D. Bienfang Rituximab for steroid-refractory chronic graft-versus-host disease Blood 108 2006 756 762
106. M. Mohty, N. Marchetti, J. El-Cheikh, C. Faucher, S. Furst, and D. Blaise Rituximab as salvage therapy for refractory chronic GVHD Bone Marrow Transplant 41 2008 909 911
107. T. Teshima, K. Nagafuji, H. Henzan, K. Miyamura, K. Takase, and M. Hidaka Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease Int J Hematol 90 2009 253 260
108. M. Okamoto, A. Okano, S. Akamatsu, E. Ashihara, T. Inaba, and H. Takenaka Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease Leukemia 20 2006 172 173
109. F. Zaja, A. Bacigalupo, F. Patriarca, M. Stanzani, M.T. Van Lint, and C. Fili Treatment of refractory chronic GVHD with rituximab: a GITMO study Bone Marrow Transplant 40 2007 273 277
110. V. Ratanatharathorn, B. Logan, D. Wang, M. Horowitz, J.P. Uberti, and O. Ringden Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation Br J Haematol 145 2009 816 824
111. M.A. Kharfan-Dabaja, A.R. Mhaskar, B. Djulbegovic, C. Cutler, M. Mohty, and A. Kumar Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis Biol Blood Marrow Transplant 15 2009 1005 1013
112. M. von Bonin, U. Oelschlagel, J. Radke, M. Stewart, G. Ehninger, and M. Bornhauser Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab Transplantation 86 2008 875 879
113. K. Le Blanc, I. Rasmusson, B. Sundberg, C. Gotherstrom, M. Hassan, and M. Uzunel Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells Lancet 363 2004 1439 1441
114. O. Ringden, M. Uzunel, I. Rasmusson, M. Remberger, B. Sundberg, and H. Lonnies Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease Transplantation 81 2006 1390 1397
115. K. Le Blanc, F. Frassoni, L. Ball, F. Locatelli, H. Roelofs, and I. Lewis Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study Lancet 371 2008 1579 1586
116. Z. Selmani, A. Naji, I. Zidi, B. Favier, E. Gaiffe, and L. Obert Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells Stem Cells 26 2008 212 222
117. H. Zhou, M. Guo, C. Bian, Z. Sun, Z. Yang, and Y. Zeng Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report Biol Blood Marrow Transplant 16 2010 403 412
118. D.C. Marcellus, V.L. Altomonte, E.R. Farmer, T.D. Horn, C.S. Freemer, and J. Grant Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease Blood 93 1999 66 70
119. H. de Lavallade, M. Mohty, C. Faucher, S. Furst, J. El-Cheikh, and D. Blaise Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation Haematologica 91 2006 1438 1440
120. A.L. Gilman, and K.R. Schultz Treatment of chronic GVHD Bone Marrow Transplant 26 2000 460 462
121. D.A. Jacobsohn, A.R. Chen, M. Zahurak, S. Piantadosi, V. Anders, and J. Bolanos-Meade Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease J Clin Oncol 25 2007 4255 4261
122. S.J. Lee, S.A. Wegner, C.J. McGarigle, B.E. Bierer, and J.H. Antin Treatment of chronic graft-versus-host disease with clofazimine Blood 89 1997 2298 2302
123. H. Greinix, and J. Antin Salvage therapy in chroinic graft versus host disease G. Vogelsang, S. Pavletic, Chronic graft versus host disease 2009 Cambridge University Press Cambridge (UK) 134 145
124. D.A. Jacobsohn, A. Rademaker, M. Kaup, and G.B. Vogelsang Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD Bone Marrow Transplant 44 2009 813 819
125. H.T. Greinix, D. Pohlreich, J. Maalouf, P. Soukup, V. Supper, and P. Kalhs A single-center pilot validation study of a new chronic GVHD skin scoring system Biol Blood Marrow Transplant 13 2007 715 723
126. D.A. Jacobsohn Shedding some LIGHT on chronic GVHD Blood 112 2008 2593 2594
127. P.A. Merkel, P.J. Clements, J.D. Reveille, M.E. Suarez-Almazor, G. Valentini, and D.E. Furst Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6 J Rheumatol 30 2003 1630 1647
128. M. Kerscher, M. Volkenandt, C. Gruss, T. Reuther, G. von Kobyletzki, and M. Freitag Low-dose UVA phototherapy for treatment of localized scleroderma J Am Acad Dermatol 38 1998 21 26
129. J. Clark, L. Yao, S.Z. Pavletic, M. Krumlauf, S. Mitchell, and M.L. Turner Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease Arch Dermatol 145 2009 918 922
130. K. Oda, C. Nakaseko, S. Ozawa, M. Nishimura, Y. Saito, and F. Yoshiba Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT Bone Marrow Transplant 43 2009 159 167
131. P.A. Merkel, N.P. Silliman, C.P. Denton, D.E. Furst, D. Khanna, and P. Emery Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial Arthritis Rheum 59 2008 699 705
132. N. Worel, D. Biener, P. Kalhs, M. Mitterbauer, F. Keil, and A. Schulenburg Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation Bone Marrow Transplant 30 2002 619 626
133. H.J. Beanlands, J.H. Lipton, E.A. McCay, A.D. Schimmer, M.E. Elliott, and H.A. Messner Self-concept as a "BMT patient", illness intrusiveness, and engulfment in allogeneic bone marrow transplant recipients J Psychosom Res 55 2003 419 425